去年秋天,当比奥泰克·菲尔姆·亨塔试图从斯隆·凯特林癌 症纪念中心将癌症研究者雷蒙德 ·沃尔吸引到他的亨塔制药公司 时,沃尔的第一个念头是公司的抗 癌构思注定要以失败告终。但在津 津有味地读过亨塔的资料后,他接 受了主要负责人这一职务。因为他 看到,在用全新方式对付癌细胞方 面,亨塔制药公司有了突破:使癌 细胞自毁。蒂尼亨塔制药公司位于 新泽西州的海茨市。它在精心研制 细胞内自毁基因的药物方面处于 领先地位。自毁基因能产生蛋白 质,通常细胞一有异常,这种蛋白 质就帮助它自毁,这称作吞噬作 用。但是癌细胞的自毁机制是有缺 陷的,因为细胞不知在何时自毁。 科学家们希望这些抗癌新药能够 恢复足够的自毁信号,然后通过化 Last fall, when Biotique Feilmhengta tried to draw cancer researcher Raymond Wall from his Sloan Kettering Cancer Memorial Center to his company, the first of Wall’s The idea is that the company’s anti-cancer concept is doomed to fail. However, after reading Henta’s data in an interesting manner, he accepted the position of chief director. Because he saw that in dealing with cancer cells in new ways, Hengta Pharmaceuticals has made a breakthrough: to destroy cancer cells. Tini Hengta Pharmaceuticals is located in Hythe, New Jersey. It is a leader in the careful development of drugs that destroy genes in cells. Self-destructing genes can produce proteins, usually abnormal cells. This protein helps it self-destruct, which is called phagocytosis. However, the self-destruction mechanism of cancer cells is flawed because cells do not know when to destroy themselves. Scientists hope that these new anti-cancer drugs will recover enough destructive signals and then pass